155 related articles for article (PubMed ID: 34178691)
1. A Novel Mice Model for Studying the Efficacy and IRAEs of Anti-CTLA4 Targeted Immunotherapy.
Xu S; Yan X; Dai G; Luo C
Front Oncol; 2021; 11():692403. PubMed ID: 34178691
[TBL] [Abstract][Full Text] [Related]
2. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.
Kumar P; Saini S; Prabhakar BS
Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481
[TBL] [Abstract][Full Text] [Related]
3. Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer.
Liu J; Blake SJ; Harjunpää H; Fairfax KA; Yong MC; Allen S; Kohrt HE; Takeda K; Smyth MJ; Teng MW
Cancer Res; 2016 Sep; 76(18):5288-301. PubMed ID: 27503925
[TBL] [Abstract][Full Text] [Related]
4. Fidelity of human ovarian cancer patient-derived xenografts in a partially humanized mouse model for preclinical testing of immunotherapies.
Odunsi A; McGray AJR; Miliotto A; Zhang Y; Wang J; Abiola A; Eppolito C; Huang RY
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33177175
[TBL] [Abstract][Full Text] [Related]
5. Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma.
Retseck J; Nasr A; Lin Y; Lin H; Mendiratta P; Butterfield LH; Tarhini AA
J Transl Med; 2018 Jul; 16(1):184. PubMed ID: 29973204
[TBL] [Abstract][Full Text] [Related]
6. Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy.
Jacoberger-Foissac C; Blake SJ; Liu J; McDonald E; Triscott H; Nakamura K; Smyth MJ; Teng MW
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33199513
[TBL] [Abstract][Full Text] [Related]
7. Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models.
Pyo KH; Kim JH; Lee JM; Kim SE; Cho JS; Lim SM; Cho BC
Lung Cancer; 2019 Jan; 127():112-121. PubMed ID: 30642538
[TBL] [Abstract][Full Text] [Related]
8. Development of a human glioblastoma model using humanized DRAG mice for immunotherapy.
Srivastava R; Labani-Motlagh A; Chen A; Bohorquez JA; Qin B; Dodda M; Yang F; Ansari D; Patel S; Ji H; Trasti S; Chao Y; Patel Y; Zou H; Hu B; Yi G
Antib Ther; 2023 Oct; 6(4):253-264. PubMed ID: 38075240
[TBL] [Abstract][Full Text] [Related]
9. Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy.
Lin S; Huang G; Cheng L; Li Z; Xiao Y; Deng Q; Jiang Y; Li B; Lin S; Wang S; Wu Q; Yao H; Cao S; Li Y; Liu P; Wei W; Pei D; Yao Y; Wen Z; Zhang X; Wu Y; Zhang Z; Cui S; Sun X; Qian X; Li P
MAbs; 2018; 10(8):1301-1311. PubMed ID: 30204048
[TBL] [Abstract][Full Text] [Related]
10. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
[TBL] [Abstract][Full Text] [Related]
11. A Potential Mechanism of Anticancer Immune Response Coincident With Immune-related Adverse Events in Patients With Renal Cell Carcinoma.
Kato T; Tomiyama E; Koh Y; Matsushita M; Hayashi Y; Nakano K; Ishizuya YU; Wang C; Hatano K; Kawashima A; Ujike T; Kawasaki K; Morii E; Gotoh K; Eguchi H; Kiyotani K; Fujita K; Nonomura N; Uemura M
Anticancer Res; 2020 Sep; 40(9):4875-4883. PubMed ID: 32878775
[TBL] [Abstract][Full Text] [Related]
12. An adapted anti-CTLA4 therapeutic aimed at mitigating the toxicities of checkpoint inhibition.
Naidoo J; Dykema A; D'Alessio F
J Clin Invest; 2019 Jan; 129(1):75-77. PubMed ID: 30530990
[TBL] [Abstract][Full Text] [Related]
13. A flexible liposomal polymer complex as a platform of specific and regulable immune regulation for individual cancer immunotherapy.
Chen CH; Weng TH; Huang HH; Huang LY; Huang KY; Chen PR; Yeh KY; Huang CT; Chien YT; Chuang PY; Lin YL; Tsai NM; Liu SJ; Su YC; Weng SL; Liao KW
J Exp Clin Cancer Res; 2023 Jan; 42(1):29. PubMed ID: 36691089
[TBL] [Abstract][Full Text] [Related]
14. Glioblastoma Organoids: Pre-Clinical Applications and Challenges in the Context of Immunotherapy.
Klein E; Hau AC; Oudin A; Golebiewska A; Niclou SP
Front Oncol; 2020; 10():604121. PubMed ID: 33364198
[TBL] [Abstract][Full Text] [Related]
15. Immune-related adverse events following administration of anti-cytotoxic T-lymphocyte-associated protein-4 drugs: a comprehensive systematic review and meta-analysis.
Xu H; Tan P; Zheng X; Huang Y; Lin T; Wei Q; Ai J; Yang L
Drug Des Devel Ther; 2019; 13():2215-2234. PubMed ID: 31308633
[No Abstract] [Full Text] [Related]
16. Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity.
Pai CS; Simons DM; Lu X; Evans M; Wei J; Wang YH; Chen M; Huang J; Park C; Chang A; Wang J; Westmoreland S; Beam C; Banach D; Bowley D; Dong F; Seagal J; Ritacco W; Richardson PL; Mitra S; Lynch G; Bousquet P; Mankovich J; Kingsbury G; Fong L
J Clin Invest; 2019 Jan; 129(1):349-363. PubMed ID: 30530991
[TBL] [Abstract][Full Text] [Related]
17. Clonality of CD4
Arakawa A; Vollmer S; Tietze J; Galinski A; Heppt MV; Bürdek M; Berking C; Prinz JC
Front Immunol; 2019; 10():1336. PubMed ID: 31275310
[TBL] [Abstract][Full Text] [Related]
18. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
19. Predictors of immunotherapy-induced immune-related adverse events.
Kartolo A; Sattar J; Sahai V; Baetz T; Lakoff JM
Curr Oncol; 2018 Oct; 25(5):e403-e410. PubMed ID: 30464691
[TBL] [Abstract][Full Text] [Related]
20. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
